Cargando…
Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment
BACKGROUND: Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic. However, as effective treatments for this disease are still unclear, safe and efficient therapies are urgently needed. Qingfei Paidu decoction (QPD) is strongly recommended in the Chinese Novel Coronavirus Pneumonia Di...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342031/ https://www.ncbi.nlm.nih.gov/pubmed/32768975 http://dx.doi.org/10.1016/j.biopha.2020.110500 |
_version_ | 1783555347844169728 |
---|---|
author | Xin, Siyi Cheng, Xueqi Zhu, Bo Liao, Xiaolong Yang, Feng Song, Lina Shi, Yan Guan, Xuefeng Su, Renyi Wang, Jian Xing, Limin Xu, Xiping Jin, Lin Liu, Yanping Zhou, Wei Zhang, Dongwei Liang, Liang Yu, You Yu, Rui |
author_facet | Xin, Siyi Cheng, Xueqi Zhu, Bo Liao, Xiaolong Yang, Feng Song, Lina Shi, Yan Guan, Xuefeng Su, Renyi Wang, Jian Xing, Limin Xu, Xiping Jin, Lin Liu, Yanping Zhou, Wei Zhang, Dongwei Liang, Liang Yu, You Yu, Rui |
author_sort | Xin, Siyi |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic. However, as effective treatments for this disease are still unclear, safe and efficient therapies are urgently needed. Qingfei Paidu decoction (QPD) is strongly recommended in the Chinese Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition). However, clinical research data on the effects of QPD on COVID-19 are scarce. Our study aimed to explore the effects of combined treatment with QPD and Western medicine on COVID-19. METHODS: In this study, 63 patients with confirmed COVID-19 were analyzed. During the first 14 days of hospitalization, patients with deteriorating symptoms were administered QPD along with Western medicine therapy (the antiviral medicine selected from interferon, lopinavir, or arbidol). The clinical characteristics and blood laboratory indices (blood routine, inflammatory factors, and multi-organ biochemical indices) were examined, and the total lung severity scores were evaluated in each patient by reviewing chest computed tomography before treatment and at the end of treatment. RESULTS: Before QPD treatment, the combined treatment group showed higher blood C-reactive protein levels and more severe pulmonary inflammation and clinical symptoms than the Western medicine treatment group. Both groups met the discharge criteria after a similar length of hospitalization. At the end of treatment, circulating white blood cells, total lymphocyte count, and glutamic-oxaloacetic transaminase levels improved dramatically in both groups (P < 0.05). In contrast, C-reactive protein, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels were improved only in the combined treatment group (P < 0.05), and C-reactive protein and creatine kinase were the most pronounced (P < 0.01). Compared with baseline, at the end of treatment, the proportion of patients with normal values of C-reactive protein, total lymphocyte count, and lactate dehydrogenase were increased in the combined treatment group (P < 0.05), whereas no significant difference was observed in the Western medicine treatment group (P > 0.05). CONCLUSION: The combination of QPD with Western medicine demonstrated significant anti-inflammatory effects compared with those of only Western medicine in patients with mild and moderate COVID-19; however, neither mortality nor length of hospitalization was affected. Moreover, the combined treatment tended to mitigate the extent of multi-organ impairment. Long-term randomized controlled trials with follow-up evaluations are required to confirm the results presented here. |
format | Online Article Text |
id | pubmed-7342031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73420312020-07-09 Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment Xin, Siyi Cheng, Xueqi Zhu, Bo Liao, Xiaolong Yang, Feng Song, Lina Shi, Yan Guan, Xuefeng Su, Renyi Wang, Jian Xing, Limin Xu, Xiping Jin, Lin Liu, Yanping Zhou, Wei Zhang, Dongwei Liang, Liang Yu, You Yu, Rui Biomed Pharmacother Article BACKGROUND: Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic. However, as effective treatments for this disease are still unclear, safe and efficient therapies are urgently needed. Qingfei Paidu decoction (QPD) is strongly recommended in the Chinese Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 6th Edition). However, clinical research data on the effects of QPD on COVID-19 are scarce. Our study aimed to explore the effects of combined treatment with QPD and Western medicine on COVID-19. METHODS: In this study, 63 patients with confirmed COVID-19 were analyzed. During the first 14 days of hospitalization, patients with deteriorating symptoms were administered QPD along with Western medicine therapy (the antiviral medicine selected from interferon, lopinavir, or arbidol). The clinical characteristics and blood laboratory indices (blood routine, inflammatory factors, and multi-organ biochemical indices) were examined, and the total lung severity scores were evaluated in each patient by reviewing chest computed tomography before treatment and at the end of treatment. RESULTS: Before QPD treatment, the combined treatment group showed higher blood C-reactive protein levels and more severe pulmonary inflammation and clinical symptoms than the Western medicine treatment group. Both groups met the discharge criteria after a similar length of hospitalization. At the end of treatment, circulating white blood cells, total lymphocyte count, and glutamic-oxaloacetic transaminase levels improved dramatically in both groups (P < 0.05). In contrast, C-reactive protein, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen levels were improved only in the combined treatment group (P < 0.05), and C-reactive protein and creatine kinase were the most pronounced (P < 0.01). Compared with baseline, at the end of treatment, the proportion of patients with normal values of C-reactive protein, total lymphocyte count, and lactate dehydrogenase were increased in the combined treatment group (P < 0.05), whereas no significant difference was observed in the Western medicine treatment group (P > 0.05). CONCLUSION: The combination of QPD with Western medicine demonstrated significant anti-inflammatory effects compared with those of only Western medicine in patients with mild and moderate COVID-19; however, neither mortality nor length of hospitalization was affected. Moreover, the combined treatment tended to mitigate the extent of multi-organ impairment. Long-term randomized controlled trials with follow-up evaluations are required to confirm the results presented here. The Authors. Published by Elsevier Masson SAS. 2020-09 2020-07-04 /pmc/articles/PMC7342031/ /pubmed/32768975 http://dx.doi.org/10.1016/j.biopha.2020.110500 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Xin, Siyi Cheng, Xueqi Zhu, Bo Liao, Xiaolong Yang, Feng Song, Lina Shi, Yan Guan, Xuefeng Su, Renyi Wang, Jian Xing, Limin Xu, Xiping Jin, Lin Liu, Yanping Zhou, Wei Zhang, Dongwei Liang, Liang Yu, You Yu, Rui Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title | Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title_full | Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title_fullStr | Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title_full_unstemmed | Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title_short | Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment |
title_sort | clinical retrospective study on the efficacy of qingfei paidu decoction combined with western medicine for covid-19 treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342031/ https://www.ncbi.nlm.nih.gov/pubmed/32768975 http://dx.doi.org/10.1016/j.biopha.2020.110500 |
work_keys_str_mv | AT xinsiyi clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT chengxueqi clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT zhubo clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT liaoxiaolong clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT yangfeng clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT songlina clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT shiyan clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT guanxuefeng clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT surenyi clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT wangjian clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT xinglimin clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT xuxiping clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT jinlin clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT liuyanping clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT zhouwei clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT zhangdongwei clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT liangliang clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT yuyou clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment AT yurui clinicalretrospectivestudyontheefficacyofqingfeipaidudecoctioncombinedwithwesternmedicineforcovid19treatment |